Drugs / Wharton Jelly Mesenchymal stem cells
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02945449 | Jan 2017 → Oct 2018 | erectile dysfunction | Sophia Al-Adwan | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT03288571 | Nov 2019 → Dec 2020 | diabetic kidney disease | Sophia Al-Adwan | Unknown | No outcome recorded |
| Phase 1/2 | NCT03299413 | Jun 2017 → Nov 2019 | inflammatory bowel disease | Hanan Jafar | Unknown | No outcome recorded |
| Phase 1/2 | NCT03751735 | Jan 2017 → Jan 2019 | erectile dysfunction | Sophia Al-Adwan | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Wharton Jelly Mesenchymal stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03288571 ↗ |
| Modality | Cell therapy | “Wharton Jelly Mesenchymal stem cells” NCT02945449 ↗ |
| Route | Other | “Intracavernous injection of Wharton Jelly Mesenchymal stem cells.” NCT02945449 ↗ |